跳至主要内容
临床试验/EUCTR2007-000973-41-SE
EUCTR2007-000973-41-SE进行中(未招募)不适用

Efficacy of cetuximab for preventing progression of CRC liver metastases after selective portal embolisation

Karolinska University Hospital, Huddinge0 个研究点目标入组 30 人开始时间: 2008年1月14日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Liver met of CRC
  • Planned for hemihepatectomy following portal embolisation of the ipsilateral liver lobe and expansion of the contralateral liver lobe.
  • Medically fit for hemihepatectomy
  • Responder to downsizing combination chemotherapy
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Extrahepatic CRC lesions
  • Known allergy to cetuximab
  • Previous exposure to cetuximab

研究者

发起方
Karolinska University Hospital, Huddinge

相似试验